Abstract
The advent of “targeted” therapy directed against the VEGF or mTOR pathways has markedly increased the survival of patients with metastatic renal cell carcinoma (RCC) over the last 5 years. Since RCC ranks 3rd in incidence-proportion percentage of brain metastases, it is not surprising, that management of this complication has become an increasingly important clinical challenge. Some form of systematic CNS screening (e.g. brain MRI scans) appears reasonable, especially at the time of disease progression or in patients with long-standing metastatic disease. Historically, surgical resection was the preferred treatment of patients with one or two superficial brain metastases. Whole brain radiotherapy (WBRT) was used for palliation of multiple or deeper metastases. Unfortunately, these approaches achieved long-term survival only in a small fraction of patients. This is because the vast majority of RCC patients do not have isolated brain recurrences, but rather progress in the brain at the time of systemic cancer progression. Advances in gamma-knife (GK) or by linear accelerator based stereotactic radiosurgery (SRS) have resulted in apparent improvement in CNS control in patients with up to 5 metastases. Long-term control of treated lesions is achieved in the majority of patients with only a single GK/SRS treatment. Whether WBRT should be immediately added is controversial. It is currently reasonable to treat with primary GK/SRS and follow patients closely for progression with the intention of using salvage therapy when appropriate. This approach shortens the delay in starting systemic therapy. The use of “targeted” therapy following GK/SRS appears to be feasible without an increased risk of CNS complications. The use of systemic immunotherapy (e.g. IL-2) following GK/SRS to induce remissions is intriguing, as about 15% of patients achieve long term or longer survival. A two-compartment approach in patients with metastatic RCC and brain involvement employing GK/SRS treatment of the brain, followed by systemic therapy is likely to result in improved outcomes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alexander E 3rd, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, Kooy HM, Loeffler JS (1995) Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 87:34–40
Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr. (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672
Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. J Am Med Assoc 295:2483–2491
Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865–2872
Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP (2010) Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16:269–278
Bukowski RM, Negrier S, Elson P (2004) Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res 10:6310S–6314S
Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037–1044
Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751
Harada Y, Nonomura N, Kondo M, Nishimura K, Takahara S, Miki T, Okuyama A (1999) Clinical study of brain metastasis of renal cell carcinoma. Eur Urol 36:230–235
Hwang SW, Abozed MM, Hale A, Eisenberg RL, Dvorak T, Yao K, Pfannl R, Mignano J, Zhu JJ, Price LL, Strauss GM, Wu JK (2009) Adjuvant Gamma Knife radiosurgery following surgical resection of brain metastases: a 9-year retrospective cohort study. J Neurooncol 98:77–82
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009 CA Cancer J Clin 59:225–249
Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC (1999) Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45:427–434
Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS (2005) Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 174:466–472; discussion 472; quiz 801
Leksell DG (1987) Stereotactic radiosurgery. Present status and future trends. Neurol Res 9:60–68
Levy DA, Slaton JW, Swanson DA, Dinney CP (1998) Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159:1163–1167
Loeffler JS (2004) Can combined whole brain radiation therapy and radiosurgery improve the treatment of single brain metastases? Nat Clin Pract Oncol 1:12–13
Manon R, O‘Neill A, Knisely J, Werner-Wasik M, Lazarus HM, Wagner H, Gilbert M, Mehta M (2005) Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E6397). J Clin Oncol 23:8870–8876
Maor MH, Frias AE, Oswald MJ (1988) Palliative radiotherapy for brain metastases in renal carcinoma. Cancer 62:1912–1917
Mathieu D, Kondziolka D, Cooper PB, Flickinger JC, Niranjan A, Agarwala S, Kirkwood J, Lunsford LD (2007) Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 60:471–481; discussion 481–472
Mehta M, Noyes W, Craig B, Lamond J, Auchter R, French M, Johnson M, Levin A, Badie B, Robbins I, Kinsella T (1997) A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases. Int J Radiat Oncol Biol Phys 39:445–454
Mori Y, Kondziolka D, Flickinger JC, Logan T, Lunsford LD (1998) Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 83:344–353
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540
O‘Neill BP, Iturria NJ, Link MJ, Pollock BE, Ballman KV, O‘Fallon JR (2003) A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys 55:1169–1176
Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. J Am Med Assoc 280:1485–1489
Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500
Pouessel D, Culine S 2007. High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor. Eur Urol
Samlowski WE, Majer M, Boucher KM, Shrieve AF, Dechet C, Jensen RL, Shrieve DC (2008) Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery. Cancer 113:2539–2548
Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, Shi WM, Wildrick DM (1998) Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42:1044–1055; discussion 1055–1046
Serizawa T, Hirai T, Nagano O, Higuchi Y, Matsuda S, Ono J, Saeki N (2010) Gamma knife surgery for 1–10 brain metastases without prophylactic whole-brain radiation therapy: analysis of cases meeting the Japanese prospective multi-institute study (JLGK0901) inclusion criteria. J Neurooncol 93:163–167
Shiau CY, Sneed PK, Shu HK, Lamborn KR, McDermott MW, Chang S, Nowak P, Petti PL, Smith V, Verhey LJ, Ho M, Park E, Wara WM, Gutin PH, Larson DA (1997) Radiosurgery for brain metastases: relationship of dose and pattern of enhancement to local control. Int J Radiat Oncol Biol Phys 37:375–383
Shuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Kabbinavar FF, Pantuck AJ, Belldegrun AS (2008) Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 113:1641–1648
Shuto T, Matsunaga S, Suenaga J, Inomori S, Fujino H (2010) Treatment strategy for metastatic brain tumors from renal cell carcinoma: selection of gamma knife surgery or craniotomy for control of growth and peritumoral edema. J Neurooncol
Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, Tans JT, Lambooij N, Metsaars JA, Wattendorff AR et al. (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33:583–590
Wowra B, Siebels M, Muacevic A, Kreth FW, Mack A, Hofstetter A (2002) Repeated gamma knife surgery for multiple brain metastases from renal cell carcinoma. J Neurosurg 97:785–793
Wronski M, Maor MH, Davis BJ, Sawaya R, Levin VA (1997) External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 37:753–759
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Loudyi, A., Samlowski, W.E. (2011). Brain Metastasis in Renal Cell Carcinoma Patients. In: Hayat, M. (eds) Tumors of the Central Nervous system, Volume 3. Tumors of the Central Nervous System, vol 3. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-1399-4_6
Download citation
DOI: https://doi.org/10.1007/978-94-007-1399-4_6
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-1398-7
Online ISBN: 978-94-007-1399-4
eBook Packages: MedicineMedicine (R0)